Cargando…
Idebenone Decreases Aβ Pathology by Modulating RAGE/Caspase-3 Signaling and the Aβ Degradation Enzyme NEP in a Mouse Model of AD
SIMPLE SUMMARY: The present study reveals that the FDA-approved drug idebenone has therapeutic effects on the pathology of Alzheimer’s disease (AD) in a mouse model. In particular, idebenone regulates pathological progression associated with Aβ by downregulating the non-amyloidogenic pathway, inhibi...
Autores principales: | Lee, Hyun-ju, Jeong, Ha-Ram, Park, Jin-Hee, Hoe, Hyang-Sook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471964/ https://www.ncbi.nlm.nih.gov/pubmed/34571815 http://dx.doi.org/10.3390/biology10090938 |
Ejemplares similares
-
Idebenone Regulates Aβ and LPS-Induced Neurogliosis and Cognitive Function Through Inhibition of NLRP3 Inflammasome/IL-1β Axis Activation
por: Lee, Hyun-ju, et al.
Publicado: (2022) -
Idebenone reduces sepsis-induced oxidative stress and apoptosis in hepatocytes via RAGE/p38 signaling
por: Gou, Tao, et al.
Publicado: (2022) -
Physicochemical Characterization and Antioxidant Activity Evaluation of Idebenone/Hydroxypropyl-β-Cyclodextrin Inclusion Complex †
por: Venuti, Valentina, et al.
Publicado: (2019) -
The effects of idebenone on mitochondrial bioenergetics
por: Giorgio, Valentina, et al.
Publicado: (2012) -
Idebenone: When an antioxidant is not an antioxidant
por: Gueven, Nuri, et al.
Publicado: (2020)